导读： 我国首个合成生物学院在天津大学揭牌，将聚焦科研突破与人才培养，推动合成生物学发展。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 天津大学合成生物与生物制造学院正式揭牌。据悉，这是我国"世界一流建设高校"中 首个合成生物学院 ，也是天津大学统筹推进教育科技人才体制机制一体改革的重要举措。 新成立的合成生物与生物制造学院将整合多学科资源，用人工智能赋能教学科研，搭建全方位 的人才培养与科研创新平台。 科研方面，学院力争实现前瞻性基础研究和引领性原创成果的重 大突破，在部分方向实现领跑；产出一批共性关键技术、前沿引领技术、颠覆性创新技术，为 我国医药健康、能源材料、生物育种和环境治理等提供科技支撑。人才培养方面，学院突破学 科限制，建立完善的专业动态调整机制，设立交叉学科课程及实践课题，为学生参与跨学科学 习和研究创造条件；还将探索"以任务带学科，以任务聚人才"的培养模式，通过重大任务和重 点项目，开展研究性项目式教学，所有学生都将参与科研项目训练，构建多学科贯通的知识体 系，形成多维能力；同时，将汇聚全球优质资源，为拔尖学 ...

Core Viewpoint - The article discusses the competitive landscape of the Chinese instrument industry as it approaches 2025, highlighting the impact of external factors such as U.S. tariffs and geopolitical risks, as well as domestic economic reforms on market dynamics [2][5]. Market Overview - The total market capitalization of 42 listed instrument companies in China reached 626.56 billion yuan, a decrease of 12.04 billion yuan compared to 2024, with an average market cap of approximately 149.18 billion yuan [4][5]. - Among these companies, 36 experienced market cap growth, with several companies seeing increases exceeding 50%, indicating a strong recovery trend in the industry [5][17]. Company Rankings - The top five companies by market capitalization are: 1. Mindray Medical: 275.92 billion yuan, down 23.98% [3][5] 2. Sunny Optical: 633.41 billion yuan, up 47.04% [3][5] 3. GD Infrared: 380.1 billion yuan, up 37.77% [3][5] 4. BGI Genomics: 295.93 billion yuan, up 39.12% [3][5] 5. Antu Biological: 220.06 billion yuan, down 26.70% [3][5] Sector Performance - The life sciences instrument sector has seen significant declines, with major players like Mindray Medical and Antu Biological experiencing substantial market cap reductions due to ongoing healthcare reforms and pricing pressures [16][14]. - In contrast, the optical instrument sector has shown strong performance, with companies like Sunny Optical and Yongxin Optical achieving notable market cap increases due to recovery in the smartphone and new energy vehicle markets [20][17]. Growth Drivers - The demand for domestic scientific instruments has surged due to U.S. export controls and renewed tariff conflicts, leading to a significant increase in the need for domestic alternatives [9][10]. - Companies such as Chuan Instruments and Juguang Technology have made significant strides in the localization of mass spectrometry and chromatography instruments, reflecting a positive trend in technological innovation and market potential [9][10]. Challenges and Outlook - Despite the positive trends, companies like He Xin Instruments face challenges with declining revenues in core segments, raising concerns about sustainability despite recent stock price increases [12][11]. - The article concludes that the competition in the instrument industry is far from over, with the potential for significant growth through technological innovation and strategic adjustments [20].

Core Viewpoint - The article discusses the recent institutional research conducted on Steel Research Nake, highlighting its national testing base layout, service coverage capabilities, advantages in instrument business, growth drivers for testing and instrument sectors, and shareholder return policies [1][2]. Company Overview - Steel Research Nake is an innovative enterprise specializing in the research, development, and application of metal material testing technology. The company offers services including testing services, analytical instruments, standard materials, capability verification services, corrosion protection engineering, and other extended testing services. Its applications span various industries such as steel, metallurgy, aerospace, nuclear power, and food [3]. Financial Performance - As of 2024, the company achieved a revenue of 1,097.67 million yuan, a year-on-year increase of 15.60%. The net profit attributable to shareholders was 145.02 million yuan, up 15.37% year-on-year. Basic earnings per share were 0.3861 yuan, reflecting a 15.25% increase. By March 31, 2025, the revenue reached 219.06 million yuan, a 7.18% increase year-on-year, with a net profit of 16.08 million yuan, up 33.28% year-on-year, and basic earnings per share of 0.0428 yuan, a 32.10% increase [4]. Testing Base Layout - The company has strategically laid out national testing bases in cities such as Beijing, Kunshan, Chengdu, Shenyang, Qingdao, Xi'an, Zhuozhou, and Zhuzhou, effectively meeting customer needs based on their distribution characteristics [5]. Instrument Business Advantages - The company’s instrument products cover over 60 types across eight categories, including atomic emission spectroscopy, mass spectrometry, gas analysis, and mechanical performance testing. Notable products include the spark direct reading spectrometer, which has won national awards, and the company leads in sales within the industry [6]. Market Opportunities - The domestic instrument industry is experiencing significant growth potential, driven by complex international conditions that accelerate the domestic replacement process, providing more opportunities for local scientific instrument manufacturers [7]. Future Development Directions - The company aims to enhance its testing and instrument businesses by exploring additional testing needs beyond metal materials, improving management efficiency, and increasing automation. In the instrument sector, the focus will be on improving product quality and expanding market share in high-end scientific instruments [8]. Growth Drivers - The growth of the company is supported by the rapid development of new materials in China and increasing demand for testing in key sectors such as aerospace and nuclear power. The scientific instrument sector is also benefiting from favorable policies, leading to accelerated domestic production [9]. Business Focus Areas - The company is focusing its testing business on high-demand areas such as aerospace and nuclear power, while also expanding into other material testing sectors, maintaining its competitive edge in metal material testing [10]. Shareholder Return Policy - The company emphasizes market value management and shareholder returns, maintaining a cash dividend policy where the proportion of cash dividends to net profit has consistently exceeded 30% in recent years [11].

Core Viewpoint - Jiangxi Province has initiated a public bidding process for the "Monitoring Capacity Construction (Phase II Project)" with a total budget of 1.08 billion yuan, aiming to procure 478 sets of various high-end analytical instruments, emphasizing the encouragement of domestic instrument procurement [2][3]. Summary by Sections Project Overview - The Jiangxi Provincial Ecological Environment Monitoring Center has launched the public bidding for the "Monitoring Capacity Construction (Phase II Project)" with a total budget of 1.08 billion yuan, planning to purchase 478 sets of various instruments [3][4]. Procurement Details - The procurement list includes multiple high-end instruments such as liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS), with specific requirements for domestic products, reflecting recognition of domestic technology and promoting local industry development [3][4]. Budget and Instrument Breakdown - The total budget for the project is 1.08 billion yuan, with detailed allocations for different packages: - New pollutant investigation monitoring capacity procurement: 834 million yuan for 15 sets [4] - Laboratory instrument updates: 727 million yuan for 1 set [4] - Drinking water source water quality monitoring capacity procurement: 881 million yuan for 19 sets [4] - Ecological environment on-site monitoring capacity procurement: 431 million yuan for 9 sets [4] - Laboratory function optimization procurement: 400 million yuan for 2 sets [4]. Specific Instrument Procurement - The procurement includes various instruments with specific budget allocations: - For Package A of new pollutant investigation: 834 million yuan for instruments like pressurized fluid extraction systems and LC-MS [5]. - For Package B: 807 million yuan for similar instruments [7]. - For Package C: 734 million yuan for high-resolution mass spectrometry [9]. - For Package D: 791 million yuan for additional LC-MS and extraction systems [11]. Contract Execution Timeline - The delivery timeline for domestic products is set at 60 days post-contract signing, while imported products have a timeline of 80 days [6][8].

Core Viewpoint - Hitachi High-Technologies Group has officially launched its tungsten filament scanning electron microscope produced at its Suzhou factory, which matches the performance of imported products, and will continue to deepen its presence in the Chinese market by providing higher quality services [2][4]. Group 1 - Hitachi High-Technologies Group is a subsidiary of the Fortune Global 500 company Hitachi Ltd, known for its cutting-edge technology and reliable quality in precision manufacturing [4]. - Since entering the Chinese market in 1964, Hitachi High-Tech has actively served Chinese customers for 60 years, adhering to the strategic concept of "In China, For China" [4]. - The company has established three major factories in China, located in Suzhou, Dalian, and Shanghai, responsible for the R&D and manufacturing of scientific instruments and medical diagnostic products, making it a crucial part of Hitachi's global manufacturing system [4]. Group 2 - In response to the changing demands of the Chinese market, Hitachi High-Tech's localization process has made significant progress with the launch of the tungsten filament scanning electron microscope in 2025, marking a further step in its localization strategy within the field of electron optics [6]. - The domestically produced tungsten filament scanning electron microscope is recognized for its excellent imaging, high automation, and stable quality, and will match the performance of imported models [6]. - Leveraging the established sales and after-sales service network of Hitachi Scientific Instruments (Beijing) Co., Ltd., the company aims to provide better services to Chinese users, committing to grow together with them [6].

导读： 有什么能比做蛋白纯化时一次轻松拿到满意的实验结果更美好的人生呢？如果有，就是再搭配一 杯咖啡，（ 文末送咖啡 ） 特别提示 因 微信调整，点击顶部"仪器信息网" → 右上方"…" → 设为" ★ "星标，否则很可能无法看到我 们的推送。 熬了一个通宵， 做蛋白抗体纯化的小D已经处在崩溃边缘 …… 话说回来，看到这种实验结果，情绪稳定的太乙真人也得崩溃。 懂的都懂 ，开盲盒式的纯化工作， 杂带多 到怀疑人生、 纯度低 的达不到预期、 得率低 的像 玩"蛋白消失术"，同样的条件纯化 结果全看"蛋白心情" ，一步没优化好久 满盘皆输 …… 还有，无尽的夜班、有毒试剂、每一步的拍照记录，纯化5小时，记录2小时…… 这种槽你还想要吐多久？ 用上 AmMa g™ Qua t ro 1 3 0 0的隔壁实验室老王 ，早就在茶水间轻松的 边喝咖啡边等实验结 果 了 。 羡慕老王，成为老王 ，请往下读： 01 AmMag™ Quat ro 1300是啥？ 蛋白纯化，手动操作繁琐、半自动流程相对复杂、花费时间巨大、各环节重复进行、科研项目 进度拖慢…… AmMa g™ Qu a tr o 1 3 0 0是 金斯瑞针对蛋白 ...

Core Viewpoint - Beijing has launched an action plan for the innovation and development of high-end scientific instruments, aiming to enhance independent innovation capabilities and cultivate leading enterprises by 2027, establishing a "1+3" industrial pattern and creating a technology source and industrial cluster [1][2]. Summary by Sections Action Plan Goals - By 2027, Beijing aims to improve its independent innovation capabilities in high-end scientific instruments, developing over 50 complete products and breaking through more than 30 key components. The plan also includes establishing recognized technical standards and attracting top scientists and engineers [3]. Industrial Cluster Development - The plan targets the cultivation of approximately 2 leading enterprises with annual revenues exceeding 3 billion yuan, over 30 enterprises with revenues exceeding 100 million yuan, more than 80 specialized and innovative enterprises, and over 200 national high-tech enterprises. The focus is on creating a collaborative "1+3" industrial pattern in Huairou, Haidian, Changping, and the Beijing Economic-Technological Development Area [3]. Ecosystem Improvement - The action plan emphasizes the establishment of service platforms for precision processing, verification, and pilot testing, along with the development of typical instrument libraries and specialized software. The goal is to enhance the self-control level of the industrial and supply chains and improve the international competitiveness of the high-end scientific instrument industry [3].

Core Viewpoint - Feina Electron Microscope has localized manufacturing in Guangzhou, maintaining its original performance and providing desktop scanning electron microscopes and solutions to support domestic demand [1][2]. Group 1: Localization and Product Offering - Feina Electron Microscope has introduced part of its scanning electron microscope production line to China, achieving localized manufacturing in its Guangzhou factory [1]. - The domestic model of Feina Electron Microscope retains the original resolution and performance, offering optimal desktop scanning electron microscope solutions to customers [1]. Group 2: Company Background and Services - Founded in 2012 in Shanghai, Feina Electron Microscope (Fina Scientific Instruments (Shanghai) Co., Ltd.) provides a range of desktop scanning electron microscopes for universities, enterprises, and research institutions [1]. - The product line includes various models such as the desktop Schottky thermal field emission scanning electron microscope, CeB6 filament XL series intelligent desktop scanning electron microscope, and the fully automatic particle and foreign matter detection scanning electron microscope [1]. - Feina Electron Microscope also offers technical support and testing services related to desktop scanning electron microscopes, with testing and after-sales service centers established in Shanghai, Beijing, Guangzhou, and Chengdu, serving over 2000 users in China [2].

导读： 2024年，哪些企业凭借战略韧性实现逆势增长？哪些企业在结构性挑战中艰难突围？未来的市场机遇又将锚定何方？ 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 随着2 0 2 4年年报季的落幕，众多国内科学仪器行业相关上市公司也陆续交出了过去一年的业绩"成绩单"。 回首2 0 2 4，在大环境持续承压，国际形势复杂多变，竞争愈演愈烈的背景下，企业利润空间不断收窄，运营成本节节攀升，下调预期、重组架 构、降薪裁员已成行业普遍现象；但另一方面，大规模设备更新重启增长"引擎"，国产仪器在政策、标准、出海之间寻找新的增长点；与此同 时，越来越多的企业选择潜心练内功，优化产品结构，全力提升产品品质与服务水平。 复杂多变的大环境进一步加剧了行业分化态势： 哪些企业凭借战略韧性实现逆势增长？哪些企业在结构性挑战中艰难突围？未来的市场机遇又 将锚定何方？ 为更好地了解分析和研究这些企业的经营策略和业务模式，仪器信息网特别制作" 2 0 2 4年国内上市仪器公司营收TOP排行榜"， 对4 6家上市企业的财报进行了全面盘点和分析，旨在为行业人士提供有价值的 ...